PDGFRA and neoplasm: 11% (17/159) of the cases with high risk or metastatic disease were not eligible for imatinib therapy due to comorbidity, patients’ refusal, too high tumor load or presence of the PDGFRA p.D842V imatinib-resistance mutation.